Anti-angiogenic polypeptides
OwnerDavid M. Waisman, Geetha Kassam +1inventors
InventorsDavid M. Waisman, Geetha Kassam, Mijung Kwon
Life of this patent
Estimating the term…
Abstract
Anti-angiogenic polypeptides A61 or p22 are disclosed. Also disclosed are methods of making the polypeptides and methods of treating subjects having angiogenic diseases or conditions.
Claims72
An isolated A61 or p22 polypeptide.
An isolated polypeptide consisting of 103, 391, or 394 contiguous amino acids of the amino terminal of plasmin.
An isolated polypeptide having a sequence as set forth in SEQ ID NO:1, SEQ ID NO:
- 2, or SEQ ID NO:3 or a conservatively substituted variant thereof.
An isolated p22 molecule which inhibits vascular endothelial cell proliferation at an IC50 of no more than 14 nM and which has a circular dichroism spectrum having a positive band at about 227.5 nm and a negative band at about 202.7 nm.
An isolated polypeptide which consists of 391 contiguous amino acids having at least 90% sequence identity with SEQ ID NO:
- 1;
- or which consists of 394 contiguous amino acids having at least 90% sequence identity with SEQ ID NO:
- 2;
- or which consists of 103 contiguous amino acids having at least 90% sequence identity with SEQ ID NO:
- 3.
A conjugate comprising A61 or p22 and a cytotoxic agent.
A nucleic acid comprising a first polynucleotide of no more than 1173 nucleotides which encode plasminogen wherein the first polynucleotide encodes a first polypeptide which consists of 391 contiguous amino acids having at least 90% sequence identity with SEQ ID NO:
- 1;
- or a second polynucleotide of no more than 1182 nucleotides which encode plasminogen wherein the second polynucleotide encodes a second polypeptide which consists of 394 contiguous amino acids having at least 90% sequence identity with SEQ ID NO:
- 2;
- or a third polynucleotide of no more than 309 nucleotides which encode plasminogen wherein the third polynucleotide encodes a third polypeptide which consists of 103 contiguous amino acids having at least 90% sequence identity with SEQ ID NO:
- 3.
A nucleic acid or complement thereto which consists of 309 nucleotides and which has at least 90% sequence identity to SEQ ID NO:
- 5;
- or which consists of 1173 nucleotides and which has at least 90% sequence identity to SEQ ID NO:
- 6;
- or which consists of 1182 nucleotides and which has at least 90% identity to SEQ ID NO:
- 7.
A nucleic acid or complement thereto which consists of 309 nucleotides and which hybridizes under stringent conditions to SEQ ID NO:
- 5;
- or which consists of 1173 nucleotides and which hybridizes under stringent conditions to SEQ ID NO:
- 6;
- or which consists of 1182 nucleotides and which hybridizes under stringent conditions to SEQ ID NO:
- 7.
A method for preparing A61 and/or p22, the method comprising:
- contacting plasminogen with a vertebrate cell;
- incubating said cell, thereby producing a product mixture comprising A61, and/or p22;
- and isolating A61 and/or p22 from the product mixture.
A method for preparing A61, the method comprising combining a plasminogen with a plasminogen activator to form a mixture, incubating the mixture in an alkaline solution, thereby producing A61;
- and isolating the A61 from the mixture.
A method for preparing p22, the method comprising combining A61 with plasmin and a reducing agent to form a mixture;
- incubating the mixture, thereby producing p22;
- and isolating the p22 from the mixture.
A method for preparing p22, the method comprising combining A61 with plasmin and annexin II tetramer to form a mixture;
- incubating the mixture, thereby producing p22;
- and isolating the p22 from the mixture.
A method for anti-angiogenic treatment of a mammal in need thereof, the method comprising administering to the mammal an angiogenesis-inhibiting amount of an A61, p22 or a combination thereof.
A method for inhibiting proliferation of vascular endothelial cells, the method comprising administering to the cells an anti-proliferation amount of A61, p22 or a combination thereof.
Dependencies are inferred from the claim text.